MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 598118 | Name: MMP-145

Description:

WARNING: This product is for research use only, not for human or veterinary use.

MMP-145 is a protease inhibitor.

Chemical Structure

MMP-145
CAS#1025717-75-2

Theoretical Analysis

MedKoo Cat#: 598118

Name: MMP-145

CAS#: 1025717-75-2

Chemical Formula: C20H20N2O7S

Exact Mass: 432.0991

Molecular Weight: 432.43

Elemental Analysis: C, 55.55; H, 4.66; N, 6.48; O, 25.90; S, 7.41

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
MMP-145; MMP 145; MMP145;
IUPAC/Chemical Name
((8-(2-oxooxazolidin-3-yl)dibenzo[b,d]furan-3-yl)sulfonyl)-L-valine
InChi Key
FWPVXLYOKAOERT-SFHVURJKSA-N
InChi Code
InChI=1S/C20H20N2O7S/c1-11(2)18(19(23)24)21-30(26,27)13-4-5-14-15-9-12(22-7-8-28-20(22)25)3-6-16(15)29-17(14)10-13/h3-6,9-11,18,21H,7-8H2,1-2H3,(H,23,24)/t18-/m0/s1
SMILES Code
CC(C)[C@@H](C(O)=O)NS(=O)(C1=CC=C2C(OC3=CC=C(N4C(OCC4)=O)C=C23)=C1)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 432.43 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Liu Y, Sun X, Wu Y, Fang P, Shi H, Xu J, Li M. Effects of miRNA-145 on airway smooth muscle cells function. Mol Cell Biochem. 2015 Nov;409(1-2):135-43. doi: 10.1007/s11010-015-2519-7. Epub 2015 Jul 22. PubMed PMID: 26197891. 2: Kou B, Gao Y, Du C, Shi Q, Xu S, Wang CQ, Wang X, He D, Guo P. miR-145 inhibits invasion of bladder cancer cells by targeting PAK1. Urol Oncol. 2014 Aug;32(6):846-54. doi: 10.1016/j.urolonc.2014.01.003. Epub 2014 Jun 20. PubMed PMID: 24954107. 3: Akter H, Park M, Kwon OS, Song EJ, Park WS, Kang MJ. Activation of matrix metalloproteinase-9 (MMP-9) by neurotensin promotes cell invasion and migration through ERK pathway in gastric cancer. Tumour Biol. 2015 Aug;36(8):6053-62. doi: 10.1007/s13277-015-3282-9. Epub 2015 Feb 28. PubMed PMID: 25724188. 4: Dey S, Ghosh N, Saha D, Kesh K, Gupta A, Swarnakar S. Matrix metalloproteinase-1 (MMP-1) Promoter polymorphisms are well linked with lower stomach tumor formation in eastern Indian population. PLoS One. 2014 Feb 5;9(2):e88040. doi: 10.1371/journal.pone.0088040. eCollection 2014. PubMed PMID: 24505369; PubMed Central PMCID: PMC3914871. 5: Wu D, Li M, Wang L, Zhou Y, Zhou J, Pan H, Qu P. microRNA 145 inhibits cell proliferation, migration and invasion by targeting matrix metallopeptidase-11 in renal cell carcinoma. Mol Med Rep. 2014 Jul;10(1):393-8. doi: 10.3892/mmr.2014.2149. Epub 2014 Apr 15. PubMed PMID: 24737449. 6: Zhao H, Kang X, Xia X, Wo L, Gu X, Hu Y, Xie X, Chang H, Lou L, Shen X. miR-145 suppresses breast cancer cell migration by targeting FSCN-1 and inhibiting epithelial-mesenchymal transition. Am J Transl Res. 2016 Jul 15;8(7):3106-14. eCollection 2016. PubMed PMID: 27508031; PubMed Central PMCID: PMC4969447. 7: Mak IW, Singh S, Turcotte R, Ghert M. The epigenetic regulation of SOX9 by miR-145 in human chondrosarcoma. J Cell Biochem. 2015 Jan;116(1):37-44. doi: 10.1002/jcb.24940. PubMed PMID: 25145279. 8: Liu Y, Wu C, Wang Y, Wen S, Wang J, Chen Z, He Q, Feng D. MicroRNA-145 inhibits cell proliferation by directly targeting ADAM17 in hepatocellular carcinoma. Oncol Rep. 2014 Nov;32(5):1923-30. doi: 10.3892/or.2014.3424. Epub 2014 Aug 20. PubMed PMID: 25174729. 9: Peng ZH, Kopeček J. Enhancing Accumulation and Penetration of HPMA Copolymer-Doxorubicin Conjugates in 2D and 3D Prostate Cancer Cells via iRGD Conjugation with an MMP-2 Cleavable Spacer. J Am Chem Soc. 2015 Jun 3;137(21):6726-9. doi: 10.1021/jacs.5b00922. Epub 2015 May 19. PubMed PMID: 25963409; PubMed Central PMCID: PMC4855854. 10: Zheng L, Pu J, Qi T, Qi M, Li D, Xiang X, Huang K, Tong Q. miRNA-145 targets v-ets erythroblastosis virus E26 oncogene homolog 1 to suppress the invasion, metastasis, and angiogenesis of gastric cancer cells. Mol Cancer Res. 2013 Feb;11(2):182-93. doi: 10.1158/1541-7786.MCR-12-0534. Epub 2012 Dec 11. PubMed PMID: 23233482. 11: Qiu T, Zhou X, Wang J, Du Y, Xu J, Huang Z, Zhu W, Shu Y, Liu P. MiR-145, miR-133a and miR-133b inhibit proliferation, migration, invasion and cell cycle progression via targeting transcription factor Sp1 in gastric cancer. FEBS Lett. 2014 Apr 2;588(7):1168-77. doi: 10.1016/j.febslet.2014.02.054. Epub 2014 Mar 5. PubMed PMID: 24613927. 12: Pal A, Melling G, Hinsley EE, Kabir TD, Colley HE, Murdoch C, Lambert DW. Cigarette smoke condensate promotes pro-tumourigenic stromal-epithelial interactions by suppressing miR-145. J Oral Pathol Med. 2013 Apr;42(4):309-14. doi: 10.1111/jop.12017. Epub 2012 Nov 23. PubMed PMID: 23173553. 13: Reihmane D, Jurka A, Tretjakovs P, Dela F. Increase in IL-6, TNF-α, and MMP-9, but not sICAM-1, concentrations depends on exercise duration. Eur J Appl Physiol. 2013 Apr;113(4):851-8. doi: 10.1007/s00421-012-2491-9. Epub 2012 Sep 19. PubMed PMID: 22990627. 14: Niu LN, Zhang L, Jiao K, Li F, Ding YX, Wang DY, Wang MQ, Tay FR, Chen JH. Localization of MMP-2, MMP-9, TIMP-1, and TIMP-2 in human coronal dentine. J Dent. 2011 Aug;39(8):536-42. doi: 10.1016/j.jdent.2011.05.004. Epub 2011 May 27. PubMed PMID: 21641958. 15: Zhu F, Liu P, Li J, Zhang Y. Eotaxin-1 promotes prostate cancer cell invasion via activation of the CCR3-ERK pathway and upregulation of MMP-3 expression. Oncol Rep. 2014 May;31(5):2049-54. doi: 10.3892/or.2014.3060. Epub 2014 Mar 5. PubMed PMID: 24604010. 16: Falzone L, Candido S, Salemi R, Basile MS, Scalisi A, McCubrey JA, Torino F, Signorelli SS, Montella M, Libra M. Computational identification of microRNAs associated to both epithelial to mesenchymal transition and NGAL/MMP-9 pathways in bladder cancer. Oncotarget. 2016 Nov 8;7(45):72758-72766. doi: 10.18632/oncotarget.11805. PubMed PMID: 27602581; PubMed Central PMCID: PMC5341942. 17: Du F, Lü LJ, Teng JL, Shen N, Ye P, Bao CD. T-614 alters the production of matrix metalloproteinases (MMP-1 andMMP-3) and inhibits the migratory expansion of rheumatoid synovial fibroblasts, in vitro. Int Immunopharmacol. 2012 May;13(1):54-60. doi: 10.1016/j.intimp.2012.03.003. Epub 2012 Mar 21. PubMed PMID: 22446297. 18: Kobalka AJ, Keck RW, Jankun J. Synergistic anticancer activity of biologicals from green and black tea on DU 145 human prostate cancer cells. Cent Eur J Immunol. 2015;40(1):1-4. doi: 10.5114/ceji.2015.50825. Epub 2015 Apr 22. PubMed PMID: 26155176; PubMed Central PMCID: PMC4472533. 19: Wang L, Ma YT, Xie X, Yang YN, Fu ZY, Liu F, Li XM, Chen BD. Association of MMP-9 gene polymorphisms with acute coronary syndrome in the Uygur population of China. World J Emerg Med. 2011;2(2):104-10. PubMed PMID: 25214993; PubMed Central PMCID: PMC4129690. 20: Boyle DL, Kim HR, Topolewski K, Bartok B, Firestein GS. Novel phosphoinositide 3-kinase δ,γ inhibitor: potent anti-inflammatory effects and joint protection in models of rheumatoid arthritis. J Pharmacol Exp Ther. 2014 Feb;348(2):271-80. doi: 10.1124/jpet.113.205955. Epub 2013 Nov 15. PubMed PMID: 24244039.